Hyblate Medical
Hybrid Catheter to Treat Atrial Fibrillation
Health Tech & Life Sciences
Non Active, Feb 2023 ceased to operate
Company Overview
Snapshot
Founded in June 2018 by Liron Tayeb, Mahmoud Suleiman, and Lior Gepstein, Hyblate Medical operates with 1–10 employees. The company received its initial funding from The Trendlines Group in August 2018.
Business overview
Hyblate Medical is a Health Tech & Life Sciences company specializing in Medical Devices, Medical Treatment & Therapeutics. The company developed the Hyblate catheter, a hybrid device designed to treat atrial fibrillation (irregular heartbeat). This technology aims to offer a safe and effective treatment by combining the benefits of existing ablation methods into a single catheter with advanced control mechanisms, serving the global healthcare market, particularly providers.
Log in to access full profile ›Company Intelligence Q&A
- What is Hyblate Medical's primary focus?
- Hyblate Medical focuses on developing medical devices, specifically a hybrid catheter, to treat atrial fibrillation, an irregular heartbeat condition.
- When was Hyblate Medical founded and by whom?
- Hyblate Medical was founded in June 2018 by Liron Tayeb, Mahmoud Suleiman, and Lior Gepstein.
- What is the core product developed by Hyblate Medical?
- The company developed the Hyblate catheter, which combines two ablation methods into a hybrid device with effective control mechanisms for treating atrial fibrillation.
- What is the current status of Hyblate Medical?
- Hyblate Medical is currently non-active, having ceased operations in February 2023.